Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Briviact oral formulations for the treatment of pediatric patients

May 15, 2018

Alkahest initiates two phase II trials of ALK-4290 in age-related macular degeneration

May 15, 2018

First patients enrolled in phase IIa trial of ORY-2001 in Alzheimer's disease

May 15, 2018

CS-1003 begins phase I trial in advanced solid tumors

May 14, 2018

Polaris collaborates with MD Anderson Cancer Center to utilize immunotherapy platform

May 14, 2018

Poseida Therapeutics presents clinical data on P-BCMA-101 for relapsed/refractory multiple myeloma

May 14, 2018

Beam Therapeutics launches with focus on creating precision genetic medicines through base editing

May 14, 2018

Human evaluation of CAR T cells targeting ROR1 underway

May 14, 2018

Medigene and bluebird bio expand TCR alliance

May 14, 2018

Tumor growth inhibition seen with Jubilant Biosys LSD1/HDAC inhibitors

May 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...